
Keywords: توسعه دارویی; TB; tuberculosis; MTB; Mycobacterium tuberculosis; MDR-TB; multi-drug resistant tuberculosis; XDR-TB; extensively drug resistant tuberculosis; TDR-TB; totally drug resistant tuberculosis; INH; isoniazid; WHO; World Health Organization; RIF; rifampicin; PZ